Not sure having skimmed through the paper that the use of Rebif 1/7 can be generalised to all users with RRMS.Patients were randomly assigned, in blinded fashion, with a computer generated list at Quintiles (Sydney, Australia), to receive either 22 µg of interferon beta-1a (Rebif, Serono, Geneva, Switzerland) or identical placebo once a week by subcutaneous injection.
This study has confirmed in a large cohort of patients at the earliest clinical stage of multiple sclerosis that brain parenchymal loss takes place rapidly, and has shown that 22 µg interferon beta-1a, given subcutaneously once weekly, can alter this process significantly. Whether higher or more frequent doses would enhance or reduce this effect remains untested. The weak correlation between new lesion formation and brain volume reduction suggests that, even at the earliest clinical phase of the disease, inflammatory demyelination is not enough to fully account for irreversible tissue loss in multiple sclerosis.
Users browsing this forum: No registered users